Celldex Therapeutics, Inc. - CLDX

SEC FilingsOur CLDX Tweets

About Gravity Analytica

Recent News

  • 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
  • 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
  • 09.09.2025 - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
  • 09.09.2025 - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
  • 09.09.2025 - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
  • 08.19.2025 - Phase 2 Topline EoE Results Conference Call & Webcast
  • 08.19.2025 - Phase 2 Topline EoE Results Conference Call & Webcast
  • 08.19.2025 - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
  • 08.19.2025 - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
  • 08.19.2025 - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Recent Filings

  • 08.19.2025 - EX-99.1 EX-99.1
  • 08.19.2025 - 8-K Current report
  • 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 08.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
  • 08.07.2025 - EX-99.1 EX-99.1